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Background: The case-crossover design is an attractive alternative to the classical case–control design which can
be used to study the onset of acute events if the risk factors of interest vary in time. By comparing exposures
within cases at different time periods, the case-crossover design does not rely on control subjects which can be
difficult to acquire. However, using the standard method of maximum likelihood, resulting risk estimates can be
heavily biased when the prevalence to risk factors is very low (or very high).
Methods: To overcome the problem of low risk factor prevalences, penalized conditional logistic regression via the
lasso (least absolute shrinkage and selection operator) has been proposed in the literature as well as related methods
such as the Firth correction. We apply and compare several penalized regression approaches in the context of a
case-crossover analysis of the European Study of Severe Cutaneous Adverse Reactions (EuroSCAR; 1997–2001).
Results: Out of 30 drugs, standard methods only correctly classified 17 drugs (including some highly implausible risk
estimates), while penalized methods correctly classified 22 drugs.
Conclusion: Penalized methods generally yield better risk classifications and much more plausible risk estimates for
the EuroSCAR study than standard methods. As these novel techniques can be easily implemented using available R
packages, we encourage routine use of penalized conditional logistic regression for case-crossover data.
Keywords: Case-crossover design, Lasso, Conditional logistic regression, Penalized regression, Severe cutaneous
adverse reactionsBackground
The case–control design is a common study design for
assessing risk factors in epidemiology. However, recruit-
ing suitable controls is a constant challenge [1]. For such
settings, case series designs have been developed. One
such type of case series is the case-crossover design [2]
where every subject or patient serves as his own control.
The association between the event of interest (e.g. disease
onset) and risk factors is estimated by comparing exposure
during the time period just prior to the event of interest
to the same subject’s exposure during a reference period.
The selection bias that case–control studies suffer
from due to having to select controls is thus avoided
by the case-crossover design. It also removes con-
founding effects from any time-invariant factors (e.g.
sex, ethnicity).* Correspondence: doerken@imbi.uni-freiburg.de
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(http://creativecommons.org/publicdomain/zeStill, case-crossover studies face many of the remaining
challenges that also affect case–control studies. In case–
control studies, risk factors with very low (or very high)
prevalence are problematic, e.g. they may result in un-
stable or unreliable estimates. Analogously, in case-
crossover studies, risk factors become problematic if they
are not very time-variant, i.e. only few subjects switch
between exposed and unexposed during the observation
period, leading consequently to few discordances. Such
data may be referred to as sparse. A second common
challenge is a potentially large number of risk factors
under investigation. Furthermore, collinearity of risk
factors is a typical problem. Many studies suffer from a
combination of these three problems. As a result, estima-
tion using standard maximum likelihood methods may be
heavily biased or may not even be possible at all.
Penalized regression methods (also known as shrinkage,
regularization, or sparse regression) have become popular
and been applied plentiful since they are particularlyle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Illustration of the timeline of the case-crossover design, shown
for four hypothetical subjects with respect to one risk factor. The dark
gray area just prior to the event of interest marks the case period, the
light gray area marks the reference period. Exposure to the risk factor is
marked by “x”. Note that subjects 1 and 2 are discordant (differing
exposures between case and reference periods), whereas subjects 3
and 4 are concordant (same exposures in case and reference periods)
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data [3, 4]. They use a modified likelihood, allowing
estimation in instances where maximizing the original
likelihood is not numerically possible.
Conditional logistic regression (CLR) using maximum
likelihood is the standard method for the analysis of
case-crossover studies; Avalos et al. [5] suggested adapt-
ing penalized methods to the CLR model and applied
their methods successfully to both simulated and real
data; they provided further applications in Avalos et al.
[6] In our article, we aim to further investigate the use
of penalized regression in case-crossover studies. We
will include the same methods that were evaluated in
Avalos et al. [5]. We do this using data from EuroSCAR
[7], a study on the very rare and severe cutaneous adverse
reactions Stevens-Johnson syndrome and toxic epidermal
necrolysis (SJS/TEN) that are often drug induced.
The EuroSCAR study is attractive for this purpose for
three reasons: firstly, it may potentially benefit from a
penalization approach since it suffers from some of the
challenges mentioned earlier. Secondly, even though Euro-
SCAR was a case–control study, here we only use data
from cases, but are then able to compare our results to the
results of the original case–control analysis, using the latter
as a benchmark. And thirdly, a successor study to Euro-
SCAR is now running a registry of SJS/TEN patients,
thereby only includes cases, which makes an assessment of
case-crossover methods in this setting is highly relevant.
We argue that penalized regression, due to the benefits in
estimation and ease of implementation, should be encour-
aged for routine use for the case-crossover design.
Methods
Study design
The motivation behind the case-crossover design is as
follows: if an exposure is prevalent right before the onset
of an event of interest (e.g. disease onset) but absent
during other times, it is natural to suspect that the ex-
posure may be a trigger of the event. As opposed to a
case–control design, the case-crossover design relies ex-
clusively on cases in order to make inferences about risk
factors. Within every case, the exposure to a time-
varying risk factor during a time interval immediately
prior to the event of interest, referred to as the case
period, is compared to the exposure during a different,
independent time window prior (or possibly also after)
the event, referred to as the reference period (see Fig. 1
for an illustration). The case-crossover design is there-
fore most suitable for studying acute events. Since case
and reference periods are compared within the same
subject, potential time-invariant confounders have no
influence. This is true for both known and unknown
confounders. The design is attractive because it spares
the difficulty of having to recruit suitable controls.Case-crossover was evaluated in the context of SJS/TEN
already in an earlier study [8]. The authors reported good
efficiency of the case-crossover estimates for the risk
factors under investigation, but with a few exceptions.
Since the case and reference periods within every sub-
ject are matched, data from a case-crossover study can
be analyzed like a conventional matched case–control
study using CLR.
Statistical analysis
For our case-crossover risk estimation, we include the
same methods that were suggested by Avalos et al. [5]. In
addition, we considered two further methods not treated
by them, namely sublasso and Firth correction.
Univariable conditional logistic regression
In a 1–1 matched study of N pairs (in the case-crossover
setting, “pair” denotes a subject’s case period that is
matched with his reference period), an estimate of a risk
factor using univariable CLR is obtained through the
log-likelihood function, which writes as







βx1n− log exp βx1nð Þ þ exp βx0nð Þð Þ½ ;
where x1n denotes the exposure during the case period
and x0n the exposure during the reference period in the
nth subject, and β is the regression coefficient [9]. The
Fig. 2 Illustration of cross-validation. The data is randomly split into
K evenly-sized blocks (in this Figure, K = 5), partitioning the data into
a training set and a test set. For each fold, a model is fit on the
training set and evaluated on the test set. The model that performs
best (i.e. has the highest likelihood) on average over all K folds is the
one that is selected
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monly used, states to use β^ as an estimate of β which




The odds ratio (OR) of exposure to a risk factor
can be directly obtained from a logistic regression
model through exp β^
 
. For risk factor analysis in the
case-crossover study of EuroSCAR, we fit separate
univariable CLR models for every risk factor.
Multivariable conditional logistic regression
In contrast to the univariable model with just one risk
factor and one estimate β, the multivariable model con-
siders a vector β = (β1, …, βp)
T of p risk factors with expos-
ure vectors x1n and x0n of length p in the log-likelihood
function, using vector multiplication accordingly [9]. This
allows for the simultaneous estimation of all risk factors in
one model, thereby adjusting their effects for each other.
Lasso
A popular penalization method is the least absolute
shrinkage and selection operator (lasso) [10]. Its popu-
larity stems from its low computation cost and it has the
property that as estimates are penalized, some are set to
exactly 0. This is the main attraction of the lasso: it per-
forms estimation and variable selection simultaneously.
Estimation is based on the penalized log-likelihood
β^ λð Þ ¼ argmax
β






where a penalty term is added to the log-likelihood that
is tuned with a penalization parameter λ ≥ 0. The par-
ameter λ controls the complexity of the model: if λ = 0,
estimation is the same as with multivariable CLR, but as
λ →∞, estimates are shrunk and eventually set to 0. To
determine an optimal value of λ, K-fold cross-validation
is used. For this, the observations of the dataset are split
into K evenly-sized blocks (while preserving the match-
ing of the pairs). Given a value of λ, estimates are
obtained by fitting a lasso model to the dataset with
observations from one of the K blocks removed (the
training set); the likelihood is then evaluated using ob-
servations from the left-out block (the test set, see Fig. 2
for clarification). This cross-validation step is performed
K times, using every block once for evaluation. Typically,
K = 5 or K = 10 is chosen; here, we use K = 10. The likeli-
hood contributions from the K cross-validation steps are
then summarized to obtain a likelihood given the value
of λ. If this procedure is performed for a range of valuesfor λ, we then choose the value for λ which maximizes
the cross-validation likelihood.
Elastic net
A common alternative to the lasso is the elastic net [10].
The penalized log-likelihood
β^ λ1; λ2ð Þ ¼ argmax
β













contains two penalty terms that are tuned via parameters
λ1,λ2 ≥ 0. If λ2 = 0, β^ becomes the lasso estimate; if λ1 = 0,
β^ is the estimator of the ridge regression [10]. Elastic net
is therefore a compromise between the lasso and ridge
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cross-validation, with the extension that maximization
is done over a grid of values for λ1 and λ2, thereby
increasing computation cost. The benefit of using the
elastic net is that it tends to be better than lasso in
selecting important variables when high correlations
are present.
Bolasso
In general, the lasso selects all the relevant variables but
additionally also a few irrelevant ones. As a remedy,
Bach suggested the bolasso [11]. With the bolasso, a
number of bootstrap samples are drawn from the data-
set, where each bootstrap sample is generated by sam-
pling N pairs from the dataset with replacement. Here,
we will draw 1000 bootstrap samples. A lasso model is
then fit to each bootstrap sample. Risk factors not se-
lected in at least 75 % of the bootstrap samples are set
to zero, the remaining risk factor estimates are set to
their average estimates from all the bootstrap samples.
Using a threshold of 75 % had the best results in Avalos
et al. [5] and was thus used by us.
Sublasso
Analogous to the bolasso method, but instead of drawing
bootstrap samples, sublasso uses subsampling by drawing
75 % of the observations without replacements. Though
sublasso was not part of the investigation by Avalos et al.
[5], we included it here as an ad hoc extension because
there are many contentions to favor subsampling over
bootstrapping [12] and because bolasso is easily extend-
able to accommodate sublasso.
Random lasso
Similar in name and principle to random forest, random
lasso is an extension of bolasso which consists of two
steps [13]. The first step is the same as the bolasso pro-
cedure, but instead of including all risk factors, for each
bootstrap sample only a random subset of size q1 of the
risk factors are used for fitting. The resulting estimates
then serve as weights in step two: lasso is again fitted to
bootstrap samples by only considering a random subset
of size q2 of the risk factors, where the risk factors are
selected proportionally to the weights determined in the
first step. In the EuroSCAR study, p = 30, therefore we
select the optimal q1 and q2 from the set 15, 20, 25 and
30 using cross-validation. As in bolasso, variables are set
to their average estimate from all bootstrap samples if
their selection is at least 75 %.
Firth correction
Similar to the lasso, Firth [14] suggested maximizing a
modified log-likelihood function,β^ ¼ argmax
β
l βð Þ þ 1
2
log detI βð Þð Þ
 
;
where I(β) is the observed information matrix, to over-
come the challenge of data separation when sample size
is small. Firth correction is another effective bias-
correction method which has gained some popularity. It
was not used by Avalos et al. [5] but it has shown good
results in a study design very similar to case-crossover
[15]. The adaptation of the Firth correction for CLR is
described by Heinze & Puhr [16] and Sun et al. [17].
Analyses were performed using R version 3.1.2. To calcu-
late correlations of risk factors, we employ the Pearson/
Spearman correlation, the two being equivalent for binary
data such as encountered here. Standard CLR was done
using the R package survival. CLR with lasso penaliza-
tion was performed using the R package clogitL1 by
Reid & Tibshirani [18] which is described in Reid &
Tibshirani [19] and is available at CRAN. Alternative R
packages for CLR with lasso are clogitLasso, also
available at CRAN, which is described in Avalos &
Pouyes [20], and in more detail in Avalos et al. [21],
and pclogit [22] available at www.columbia.edu/
~sw2206/softwares.htm. To implement the Firth correc-
tion, we used a macro CFL by Heinze available at
http://cemsiis.meduniwien.ac.at/en/kb/science-research/
software/statistical-software/fllogistf/ which was run
using SAS version 9.2. The package coxphf [23] provides
an implementation of the Firth regression in R for the Cox
model. Since the likelihood for a CLR model is equivalent
to that of a Cox model with a particular data structure, this
package is a suitable alternative. Our R and adapted SAS
scripts are available in the supplementary material.
Study population
We apply the methods under investigation using patient
data from the EuroSCAR study [7]. The study was de-
signed as a multinational case–control study on patients
with SJS/TEN. As these events are mainly caused by a
variety of drugs, the main aim was to assess the risk of
drugs or drug groups.
The recruitment of cases and controls took place in
six countries (Austria, France, Germany, Israel, Italy, and
The Netherlands) within the period from April 1997 to
December 2001. Altogether, 379 cases and 1,505 con-
trols were included. From the obtained data, 30 drug
groups (henceforth simply referred to as drugs) were
defined as either “highly suspected” (n = 9), “suspected”
(n = 10), or not suspected (“other”, n = 11) of causing
SJS/TEN. These classifications were corroborated by
Papay et al. [24]. For more details on the EuroSCAR
study, we refer the reader to Mockenhaupt et al. [7].
For the case-crossover analysis, only the 379 cases of
the EuroSCAR study were extracted. 22 patients were


































































Fig. 3 Estimates from the multivariable CLR plotted against the
estimates from the case–control study (Mockenhaupt et al. [7]). The
line marks the 45-degree line of equality (note the different scales
on the x- and the y-axis). Ideally, the estimates from the multivari-
able CLR would resemble the estimates from the case–control study;
however, some very large discrepancies are apparent. Displayed next
to the estimates is the minimum of the two possible discordances
between case and reference period of the risk factor. It can be seen
that drugs with extreme estimates have only one or zero such dis-
cordances, while drugs with at least two discordances have
plausible estimates
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vant drugs during the observation period and thus could
not contribute any information to the estimations. A fur-
ther 6 patients were excluded because their observation
period was too short to accommodate the minimum re-
quired number of days for both the case and reference
period, leaving a total of 351 subjects for our analysis.
The data used in our analysis is available in the supple-
mentary material (see Additional file 1).
Evaluation of methods
In our work, the goal of the competing methods is to
perform a new classification, herein called reclassifica-
tion, of the drugs that would ideally resemble the classi-
fications of the case–control study of EuroSCAR [7],
thus the latter will serve as a benchmark. Using solely
the estimates of the case–control study (Additional file 2:
Table S1), the best resemblance of risk classes is obtained
by deeming drugs “highly suspected” if log OR > 2.4,
“suspected” if 0.45 < log OR < 2.4 and “other” if log OR <
0.45. Further, we employ receiver operating characteristic
(ROC) curves by discriminating which drugs are correctly
reclassified as “highly suspected”, and alternatively by
discriminating which drugs are correctly reclassified
as “highly suspected” or “suspected”.
Results
Correlations of drugs within case periods, and separately
within reference periods, were all considerably low
(<0.32 in absolute value).
Estimates from a multivariable CLR, arguably the most
common technique for analyzing matched data, suffer
from drugs that are prevalent in subjects’ case periods
but infrequent in the reference periods, or vice versa.
Only cases with discordant exposure in both periods
contribute to the likelihood, thus drugs with only few
discordances prove to be problematic for analysis. For
such drugs, resulting risk estimates tend to be implaus-
ible, either because they are too large or too small.
Figure 3 displays the estimates of the multivariable CLR
model plotted against the estimates from the benchmark
case–control study. Ideally, the estimates of the former
would agree with the latter, in which case the plotted
points would fall on the 45 degree line. However, there are
some very large disagreements between the two. As indi-
cated by the numbers next to the plotted points, it appears
to occur only (though not necessarily) for drugs with in-
frequent discordances. Therefore, multivariable CLR is
very unsatisfactory for obtaining plausible risk estimates.
Figure 4a shows the risk estimate paths of the lasso for
different values of the tuning parameter λ. As the tuning
parameter increases, the risk estimates shrink and are
eventually zero. Cross-validation determines the opti-
mal value of λ and is marked by the vertical dashedline (see Additional file 2: Figure S1 for illustration). These
optimal risk estimates are shown in Fig. 4b. They agree
much better with the estimates of the benchmark case–
control study. There no longer is a problem of highly im-
plausible values.
Table 1 is a summary of the number of correctly reclassi-
fied drugs according to the classification by Mockenhaupt
et al. [7] (see Additional file 2: Table S2 for a detailed
version). Multivariable CLR performs worst overall
among all the methods and only correctly reclassifies
17 out of 30 drugs. The penalized methods show
large improvements, with lasso and random lasso per-
forming best, and similar results from elastic net,
sublasso and Firth correction.
The arguably most important aspect of the EuroSCAR
study was to correctly identify drugs that are highly
suspected of causing SJS/TEN. This poses a binary
discrimination problem (“highly suspected” versus
“suspected” or “other”) for which we use ROC curves
that do not rely on a single fixed cut-off value to dis-
criminate between risk classes.
Figure 5 shows a comparison of ROC curves for multi-
variable CLR and the lasso. Note that due to the shrink-

































































Fig. 4 a Estimates of the lasso for different values of λ. As λ increases, risk estimates shrink and are eventually 0. The dashed line marks the
optimal λ-value and the corresponding optimal estimates, as determined by cross-validation. b Similarly to Fig. 3, the optimal lasso estimates are
plotted against the benchmark case–control estimates. Agreement between the two is evidently much better than for multivariable CLR. The line
marks the 45-degree line of equality. The y-scale is chosen to accommodate comparisons with Fig. 3
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lasso have the same or similar specificity, the lasso uses
a much lower log OR cut-off. It can be seen that the
ROC curve of lasso is largely superior to the ROC curve
of the multivariable CLR model. Therefore, the lassoTable 1 Number of drugs correctly identified under new















log OR < 0.45
Total
(n = 30)
Univariable CLR 5 7 7 19
Multivariable CLR 6 2 9 17
Lasso 5 8 9 22
Elastic net 4 8 9 21
Bolasso 4 6 9 19
Sublasso 4 8 9 21
Random lasso 6 6 10 22
Firth correction 5 8 7 20
Case-controla 9 10 8 27
aNote that even though the case–control study was the basis for the risk
classification in Mockenhaupt et al. [7], its estimates do not fully agree with
the reclassification scheme used by us. This is because experts classified some
of the drugs differently than its risk estimates would suggest based on their
experience and opinion, whereas we employ a reclassification scheme using
only the estimatesoutperforms multivariable CLR in discriminating highly
suspected drugs.
Summarizing ROC curves for all methods with their
area under the curve, Table 2a shows that lasso, elas-
tic net and Firth correction perform best for correctly
identifying highly suspected drugs. Multivariable CLR
again performs worst, and the resampling methods
fall in-between.
We also look at which methods best discriminate be-
tween risk classes “highly suspected” or “suspected” ver-
sus “other”. Again the lasso performs better overall than
multivariable CLR. Among all methods, Table 2b shows
that Firth correction and elastic net have the best ability
to discriminate in this setting. The robustness of these
results is corroborated by a sensitivity analysis wherein
the AUCs were calculated for 100 subsamples drawn
without replacement (Additional file 2: Figure S2). Inter-
estingly, the benchmark case–control study performs ra-
ther poorly here. A possible explanation could be that in
the case–control study by Mockenhaupt et al. [7] some
drugs were classified as “other” simply because they were
newly introduced, when in fact their estimates would
suggest that they are “suspected” or “highly suspected”.
Therefore, an assessment of the supposedly “correct”
case–control risk estimates alone need not necessarily
lead to the best discrimination scheme.



























Fig. 5 ROC curves of multivariable CLR and the lasso for reclassifying
highly suspected drugs. Cut-off values of the log ORs for discriminating
between highly suspected drugs versus suspected or other drugs
range from 0 to 4; the sensitivity and 1-specificity of several
cut-off values are highlighted. A 45-degree line of equality is
added for reference
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Summary of our work
Penalized regression has been introduced in the litera-
ture as a method for bias-correction and has many ap-
plications; here, we argue in favor of it in the context of
the case-crossover design. Similarly to a previous study,
we evaluated the case-crossover design in the context of
Stevens-Johnson syndrome and toxic epidermal necroly-
sis (SJS/TEN) [8]. Using data from the EuroSCAR study
[7], the superiority of the lasso over multivariable condi-
tional logistic regression (CLR) was apparent, since the
latter seemingly suffered from the problem of sparse
data.Table 2 Area under the curve for binary discrimination of drugs
a) AUC for “highly
suspected drugs“
b) AUC for “highly suspected
drugs“ or “suspected drugs“
Univariable CLR 0.836 0.871
Multivariable CLR 0.741 0.775
Lasso 0.862 0.861
Elastic net 0.868 0.909
Bolasso 0.804 0.813
Sublasso 0.815 0.823
Random lasso 0.820 0.847
Firth correction 0.852 0.928
Case-controla 0.947 0.809
asee footnote in Table 1We also investigated several resampling approaches
together with penalization methods. They did not dem-
onstrate any improvement, thus our results suggest that
the increased computation cost is not justified. The Firth
correction performed reasonably compared to the penal-
ized methods and was even best in discriminating “highly
suspected” or “suspected” drugs. This is particularly note-
worthy when considering that the other penalized methods
tune their penalty terms whereas the Firth correction uses
a constant factor of 0.5. It may be an interesting investiga-
tion to explore if a similarly tuned Firth correction would
be an appropriate extension.
There are several limitations to our study. First and
foremost, although we enjoyed the advantage of having
benchmark case–control estimates for our case-crossover
analysis, the benchmark is not perfect since the original
case–control study had its own limitations. Because of its
limitations, some of the risk factors of the case–control
study could be estimated only through univariable CLR.
However, univariable estimates may not be the best
benchmark for comparing multivariable methods. Also,
when single cut-off values are used to compare all
methods (as was done for Table 1), direct comparisons of
estimators may not be suitable when some methods
shrink estimates and some do not. For this reason, we also
used ROC curves which do not rely on single cut-off
values. Further, assessment solely based on estimates may
be incomplete without also considering standard errors of
the estimates. This, however, is a weakness of the lasso, as
standard errors are not directly available [25, 26]. For a
further discussion on the limitations of penalized regres-
sion, see Greenland et al. [27].
Penalized regression in epidemiology and
case-crossover
A good introduction to penalized regression is given by
Cole et al. [4]. However, epidemiologic literature on pe-
nalized regression is still relatively scarce. An example of
an exception is Rose [28] who developed risk scores for
mortality prediction using, among other techniques, pe-
nalized regression. In another study, Burgette et al. [29]
implement the lasso and elastic net to model adverse
birth outcomes. Further, Smith et al. [30] apply penalized
regression to model the BMI in a longitudinal study.
In a large study that uses case-crossover with CLR,
Mostofsky et al. [31] investigate the association be-
tween particle constituents of air pollution and health
outcomes. Theirs is a great example where penalized
regression could be applied since their risk factors
suffer from high collinearity.
Sullivan & Greenland [32] point out that sparse-data ar-
tefacts often go unrecognized in study reports. They pro-
vide an example of a case–control study which reported an
odds ratio between ever having smoked and ICU
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ing the plausibility of the estimate. Cole et al. [4] stress the
importance of penalized regression by pointing out that
“[…] epidemiologists are aware of problems due to
sparse-data bias in very small studies, but sparse-data
bias appears to be less widely recognized when it
occurs in larger studies.” (p. 257)
Among the attractive features in favor of penalized
methods is that the shrinkage of coefficients is proportional
to the estimated variance of the coefficients, thus unstable
estimates are shrunk more than stable ones. And further,
penalized regression can be applied when covariates are
collinear and conventional methods fail completely [3].
In the context of case-crossover, there has been hardly
any work on using penalized regression. Walter &
Tiemeier [33] conducted a survey of 300 articles published
in four major epidemiologic journals, not one of which
used penalized regression. Though their work is no longer
up to date, a recent literature search revealed only
three articles that use penalized regression in the context
of case-crossover, all by Avalos and her colleagues
(Additional file 2: Table S3).
In a study design closely related to case-crossover, the
self-controlled case series design, work in the literature
on penalization methods has been equally scarce. The
self-controlled case series is tantamount to the classical
cohort study in the same way that case-crossover is the
case series equivalent of a classical case–control study
[34]. In a work using the self-controlled case series de-
sign, Zeng et al. [15] study bias correction methods for
datasets with a small number of adverse events (i.e. a
sparse data), such as a vaccine safety study. In it, the
Firth estimate consistently outperformed the classical
maximum likelihood estimate.
In a recent work by Avalos et al. [35], the authors de-
scribe in detail an algorithm more efficient than the one
in their initial paper [5], making it suitable even for large
datasets. The authors also provide a good comparison of
the different R packages available that implement the
lasso in CLR (and also Cox and unconditional logistic
regression).
Conclusion
Standard maximum likelihood is the default in most
statistical software packages and has many desirable large-
sample properties, among them asymptotic unbiasedness.
The large-sample condition, however, is difficult to
achieve satisfactorily, and consequently, bias can be
substantial for small-sample studies.
Therefore, arguments are strong for wider use of penal-
ized regression in epidemiological studies. Of great prac-
tical importance is that penalized regression is easilyimplemented for linear, Poisson, Cox, or CLR models. For
comparison, running a CLR requires two lines of code in R:Running the lasso is only marginally more work, re-
quiring three lines:Avalos et al. [36] recommend penalized regression as
an alternative to conventional strategies, and Cole et al.
[4] even suggest that penalized likelihood should argu-
ably replace standard maximum likelihood as the default
method. For the case-crossover design, we also encour-
age penalized regression for routine use.
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